---
name: Hongene Biotech Corporation
slug: hongene
site: cdmo
website_domain: hongene.com
summary: Hongene is a vertically-integrated CDMO offering end-to-end oligonucleotide and mRNA manufacturing from raw materials to GMP drug product, with nearly 30 years of RNA-focused expertise and tonne-scale production capacity.
tagline: End-to-end RNA manufacturing from raw materials to GMP drug product with 30 years of expertise.
founded_year: 1998
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: 
tier2_domain_verified: false
updated_at: 2026-08-02T07:02:45.540Z
services_count: 12
modalities_count: 2
indications_count: 0
locations_count: 0
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Hongene Biotech Corporation

End-to-end RNA manufacturing from raw materials to GMP drug product with 30 years of expertise.

Listed on cdmo.directory.

## Summary

Hongene is a vertically-integrated CDMO offering end-to-end oligonucleotide and mRNA manufacturing from raw materials to GMP drug product, with nearly 30 years of RNA-focused expertise and tonne-scale production capacity.

## At a glance

- Founded: 1998

## Services

- CMC Analytical Development
- Formulation Development
- Process Development
- Stability Testing & Storage
- Quality Control Testing
- Oligonucleotide Manufacturing
- mRNA Manufacturing
- Lipid Nanoparticle (LNP) Formulation
- Lyophilization (Freeze Drying)
- Sterile Fill-Finish & Aseptic Manufacturing
- Technology Transfer
- CMC Regulatory Submission Support

## Modalities

- Oligonucleotide
- mRNA

## Long description

## Overview

Hongene Biotech Corporation is a specialized CDMO focused on nucleic acid manufacturing, with nearly 30 years of RNA-focused expertise. The company operates a vertically-integrated platform spanning raw materials production through advanced CDMO services, reducing handoffs and accelerating timelines for oligonucleotide and mRNA therapeutic programs.

## Core Services

**Oligonucleotide CDMO**
- Process and analytical development with chemoenzymatic ligation technology for high-purity, scalable siRNA, sgRNA, and other oligonucleotides
- GMP production up to tonne scale
- Quality control, regulatory support, and release testing

**mRNA CDMO**
- Plasmid DNA template generation and linearization
- One-pot in vitro transcription (IVT) with integrated plasmid linearization
- Capping with proprietary HiXCap™ technology for improved translation efficiency
- Purification and QC (≥98% full-length, dsRNA <0.01%)
- LNP formulation, lyophilization, and aseptic fill–finish

**Custom Synthesis**
- Tailored nucleotides, phosphoramidites, linkers, and specialty reagents
- Portfolio of over 2,000 SKUs including phosphoramidites, GalNAc conjugates, linkers, NTPs, cap analogs, and enzymes
- Rapid turnaround for bespoke requests

## Technical Capabilities

**Development Services**
- CMC: Process development & optimization, formulation development, non-GMP and GMP batches, FTE model
- Analytical: Method development & validation, impurity profiling, raw material and intermediate testing, ICH stability testing, release testing
- Commercial Manufacturing: Process Performance Qualification (PPQ), GMP manufacturing trains, global regulatory filing support (CDE/FDA/EMA)

**Raw Materials Manufacturing**
- In-house manufacture of all key building blocks at commercial scale
- World-leading production capacity for phosphoramidites, GalNAc conjugates, linkers, NTPs, cap analogs, and enzymes

## Differentiation

Hongene leverages proprietary technologies including chemoenzymatic ligation for scalable oligonucleotide synthesis and HiXCap™ for cost-effective mRNA optimization. The company is an ACS Green Chemistry Institute member, pioneering solvent recycling and enzymatic synthesis to reduce environmental impact. Vertically-integrated operations ensure regulatory alignment and quality control across the entire value chain from discovery through commercial manufacturing.

## Related companies

- [Biospring](/companies/biospring) (CMC Analytical Development, Process Development) — [Compare](/compare/biospring/hongene)
- [MyBiotech GmbH](/companies/mybiotech) (CMC Analytical Development, Formulation Development) — [Compare](/compare/hongene/mybiotech)
- [Sophia CDMO](/companies/sophiacdmo) (CMC Analytical Development, Process Development) — [Compare](/compare/hongene/sophiacdmo)
- [Fujifilm Pharmaceuticals U.S.A., Inc](/companies/fujifilmpharma) (Formulation Development, Process Development) — [Compare](/compare/fujifilmpharma/hongene)
- [TriLink BioTechnologies](/companies/trilinkbiotech) (CMC Analytical Development, Process Development) — [Compare](/compare/hongene/trilinkbiotech)
- [Bachem](/companies/bachem) (CMC Analytical Development, Formulation Development) — [Compare](/compare/bachem/hongene)
- [Ascendia Pharmaceutical Solutions](/companies/ascendiapharma) (CMC Analytical Development, Formulation Development) — [Compare](/compare/ascendiapharma/hongene)
- [Alcami Corporation](/companies/alcaminow) (CMC Analytical Development, Formulation Development) — [Compare](/compare/alcaminow/hongene)

_Profile last updated: 2026-08-02T07:02:45.540Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.